Skip to content
Search

Latest Stories

Do not sell plastic containers or utensils containing bamboo: Businesses in Great Britain told

Do not sell plastic containers or utensils containing bamboo: Businesses in Great Britain told

This advice applies only to products combining plastic and plant-based materials, not those made solely from bamboo or plant-based substances 

The Food Standards Agency (FSA) and Food Standards Scotland (FSS) are reminding businesses in Great Britain (GB) not to sell plastic containers and utensils containing bamboo and other unauthorised plant-based materials due to non-compliance with legislation and safety concerns.

Consumers are also advised to avoid using these products for food-related purposes.


This guidance follows a conclusion by the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) that bamboo and similar plant-based matter in plastic materials can cause formaldehyde and melamine to leak into food or drink above the legal limits, posing health risks.

While formaldehyde is naturally produced by the body,  ingestion at high levels can cause gastrointestinal issues. Melamine, although having low acute toxicity when consumed short-term, can lead to kidney and urinary tract damage with long-term high-level exposure.

In May 2022, the FSA and FSS directed the industry to ban sales of food contact materials containing bamboo and similar unauthorised plant-based substances like rice husks, wheat straw, and hemp. They also called for evidence to assess the long-term safety of these products.

After reviewing new data, the COT found insufficient evidence to ensure these products' safety, maintaining concerns about their impact on health from long-term use.

Although short-term use of these products is unlikely to pose immediate health risks, the FSA and FSS recommend reducing exposure due to the uncertain long-term effects.

Dr James Cooper, deputy director of food policy at the FSA said: “Following our robust risk assessment process, we have found there to be insufficient evidence to provide us with confidence that these products are safe for consumers to use and therefore, our position remains that food containers and utensils containing bamboo composite material should not be sold in GB.

“We don’t know the long-term impacts to health from using these products and we continue to have concerns that chemicals such as formaldehyde and melamine might leak from these materials when they are in contact with food, especially hot or acidic foods.”

Since these items are neither compostable nor recyclable, the FSA advises consumers to discard them in general waste bins or re-use them for non-food purposes.

The sale of these products as food contact material has already been prohibited in Northern Ireland, following the European Commission Food Contact Material legislation, and businesses continue to comply with this ruling.

This advice applies only to products combining plastic and plant-based materials, not those made solely from bamboo or plant-based substances.

Businesses are being asked to ensure that any bamboo or similar plant products on the market do not contain plastic components.

 

 

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less